CLDN19 adenovirus

The CLDN19 gene encodes claudin-19, a key component of tight junction proteins that regulate paracellular permeability and maintain cell polarity in epithelial and endothelial tissues. Claudin is an integral membrane protein that forms the backbone of tight junctions and is essential for the barrier function of organs such as the kidney, retina, and inner ear. Specifically, CLDN19 plays a crucial role in renal electrolyte reabsorption and retinal homeostasis. Mutations in this gene are associated with several serious human diseases, including familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), as well as ocular damage such as retinal degeneration. Due to its physiological significance, CLDN19 has become a target for gene therapy research, especially for diseases caused by its dysfunction or defect.

CLDN19 adenovirus is a recombinant viral vector designed to deliver the CLDN19 gene to target cells for research or therapeutic purposes. Adenoviral vectors are widely used in gene therapy due to their high transduction efficiency, broad tropism, and ability to infect both dividing and non-dividing cells. CLDN19 adenovirus is particularly important for studying the role of CLDN19 in tight junction formation, epithelial barrier function and disease mechanisms. In addition, it has the potential to treat CLDN19-related diseases by restoring normal protein expression in affected tissues (such as the kidney or retina). Preclinical studies using CLDN19 adenovirus have demonstrated its ability to effectively rescue cell phenotypes in disease models, highlighting its potential for future clinical applications.